HLX15-SC

A Randomized, Double-blind, Parallel-controlled Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Near Add Your Location

Sorting 9 by

Vista Oncology Inc.
Olympia, WA
  • Accepting patients
Ocala Oncology Center
Ocala, FL
  • Accepting patients
Oncology Consultants PA
Houston, TX
  • Accepting patients
Highlands Oncology Group
Springdale, AR
  • Accepting patients
Pontchartrain Cancer Center
Covington, LA
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.